These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 11297751)

  • 1. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).
    Bouma BN; Marx PF; Mosnier LO; Meijers JC
    Thromb Res; 2001 Mar; 101(5):329-54. PubMed ID: 11297751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).
    Bouma BN; Meijers JC
    J Thromb Haemost; 2003 Jul; 1(7):1566-74. PubMed ID: 12871292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into factors affecting clot stability: A role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R).
    Bouma BN; Meijers JC
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):13-9. PubMed ID: 14872415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex.
    Bajzar L; Morser J; Nesheim M
    J Biol Chem; 1996 Jul; 271(28):16603-8. PubMed ID: 8663147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Regulatory mechanism of fibrinolysis system by thrombin activatable fibrinolysis inhibitor (TAFI)].
    Urano T
    Nihon Yakurigaku Zasshi; 2000 Nov; 116(5):298-303. PubMed ID: 11215380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP; Blombäck M
    Thromb Res; 2002 Apr; 106(1):59-62. PubMed ID: 12165290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteolytic activation of purified human procarboxypeptidase U.
    Schatteman KA; Goossens FJ; Scharpé SS; Hendriks DF
    Clin Chim Acta; 2000 Feb; 292(1-2):25-40. PubMed ID: 10686274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor XI dependent and independent activation of thrombin activatable fibrinolysis inhibitor (TAFI) in plasma associated with clot formation.
    Bouma BN; Mosnier LO; Meijers JC; Griffin JH
    Thromb Haemost; 1999 Dec; 82(6):1703-8. PubMed ID: 10613658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis].
    Stasko J; Hudecek J; Kubisz P
    Vnitr Lek; 2004 Jan; 50(1):36-44. PubMed ID: 15015228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.
    Bajzar L; Nesheim ME; Tracy PB
    Blood; 1996 Sep; 88(6):2093-100. PubMed ID: 8822928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
    Antovic JP; Schulman S; An SS; Greenfield RS; Blombäck M
    Scand J Clin Lab Invest; 2004; 64(8):745-51. PubMed ID: 15719893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombin-activatable fibrinolysis inhibitor.
    Marx PF
    Curr Med Chem; 2004 Sep; 11(17):2335-48. PubMed ID: 15379716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.
    Von dem Borne PA; Bajzar L; Meijers JC; Nesheim ME; Bouma BN
    J Clin Invest; 1997 May; 99(10):2323-7. PubMed ID: 9153272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B).
    Boffa MB; Reid TS; Joo E; Nesheim ME; Koschinsky ML
    Biochemistry; 1999 May; 38(20):6547-58. PubMed ID: 10350473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis.
    van Tilburg NH; Rosendaal FR; Bertina RM
    Blood; 2000 May; 95(9):2855-9. PubMed ID: 10779431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors.
    Juhan-Vague I; Renucci JF; Grimaux M; Morange PE; Gouvernet J; Gourmelin Y; Alessi MC
    Arterioscler Thromb Vasc Biol; 2000 Sep; 20(9):2156-61. PubMed ID: 10978263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human procarboxypeptidase B: three-dimensional structure and implications for thrombin-activatable fibrinolysis inhibitor (TAFI).
    Barbosa Pereira PJ; Segura-Martín S; Oliva B; Ferrer-Orta C; Avilés FX; Coll M; Gomis-Rüth FX; Vendrell J
    J Mol Biol; 2002 Aug; 321(3):537-47. PubMed ID: 12162965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A.
    Antovic J; Schulman S; Eelde A; Blombäck M
    Haemophilia; 2001 Nov; 7(6):557-60. PubMed ID: 11851753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis.
    Nesheim M; Wang W; Boffa M; Nagashima M; Morser J; Bajzar L
    Thromb Haemost; 1997 Jul; 78(1):386-91. PubMed ID: 9198184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of mouse thrombin-activatable fibrinolysis inhibitor.
    Marx PF; Wagenaar GT; Reijerkerk A; Tiekstra MJ; van Rossum AG; Gebbink MF; Meijers JC
    Thromb Haemost; 2000 Feb; 83(2):297-303. PubMed ID: 10739389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.